A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma

References

• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: b-cell lymphomas, version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650–661. doi:10.6004/jnccn.2019.0029
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi:10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861. doi:10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–2048. doi:10.1182/blood.2019002729
   PubMed Web of Science ®Google Scholar
• Marcus C, Maragkos GA, Alterman RL, Uhlmann E, Pihan G, Varma H. GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas. J Clin Neurosci. 2021;83:49–55. doi:10.1016/j.jocn.2020.11.031
   PubMed Web of Science ®Google Scholar
• Roh J, Cho H, Yoon DH, et al. Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. Sci Rep. 2020;10(1):10680. doi:10.1038/s41598-020-67738-4
   PubMed Web of Science ®Google Scholar
• Bouroumeau A, Bussot L, Bonnefoix T, et al. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma. J Pathol Clin Res. 2021;7(6):604–615. doi:10.1002/cjp2.223
   PubMedGoogle Scholar
• Alsaadi M, Khan MY, Dalhat MH, et al. Dysregulation of miRNAs in DLBCL: causative factor for pathogenesis, diagnosis and prognosis. Diagnostics. 2021;11(10). doi:10.3390/diagnostics11101739
   Web of Science ®Google Scholar
• Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg. 2021;273(3):532–541. doi:10.1097/sla.0000000000003370
   PubMed Web of Science ®Google Scholar
• Schiefer S, Wirsik NM, Kalkum E, et al. Systematic review of prognostic role of blood cell ratios in patients with gastric cancer undergoing surgery. Diagnostics. 2022;12:3.
   Web of Science ®Google Scholar
• Wu XB, Hou SL, Liu H. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients. World J Clin Cases. 2021;9(32):9825–9834. doi:10.12998/wjcc.v9.i32.9825
   PubMed Web of Science ®Google Scholar
• Gradel KO, Larsen TS, Frederiksen H, et al. Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma. Ann Med. 2022;54(1):713–722. doi:10.1080/07853890.2022.2046287
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang J, Luo S, Zhao X. Prognostic significance of systemic immune-inflammation index in patients with diffuse large B-cell lymphoma. Front Oncol. 2021;11:655259. doi:10.3389/fonc.2021.655259
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu H, Zhang Q, et al. Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-cell lymphoma. Asia Pac J Clin Oncol. 2022;19:e138–e148. doi:10.1111/ajco.13806
   PubMed Web of Science ®Google Scholar
• Shen Z, Wang F, He C, et al. The Value of Prognostic Nutritional Index (PNI) on newly diagnosed diffuse large B-cell lymphoma patients: a multicenter retrospective study of HHLWG based on propensity score matched analysis. J Inflamm Res. 2021;14:5513–5522. doi:10.2147/jir.S340822
   PubMed Web of Science ®Google Scholar
• He J, Yin H, Xia Y, et al. Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma. Leuk Res. 2021;110:106664. doi:10.1016/j.leukres.2021.106664
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim SJ, Hwang D, et al. The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J. 2014;55(6):1568–1575. doi:10.3349/ymj.2014.55.6.1568
   PubMed Web of Science ®Google Scholar
• Liu T, Ye F, Li Y, Liu A. Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large B-cell lymphoma. Ann Palliat Med. 2021;10(9):9650–9659. doi:10.21037/apm-21-2067
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36(10):1085–1093. doi:10.1093/carcin/bgv123
   PubMed Web of Science ®Google Scholar
• Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–126. doi:10.4103/aam.aam_56_18
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.Can-18-3962
   PubMed Web of Science ®Google Scholar
• Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103(33):12493–12498. doi:10.1073/pnas.0601807103
   PubMed Web of Science ®Google Scholar
• Yoon CI, Park S, Cha YJ, et al. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. Breast. 2020;50:141–148. doi:10.1016/j.breast.2019.09.013
   PubMed Web of Science ®Google Scholar
• Cefalì M, Efstathopoulou A, De Dosso S, Saletti P. Lymphocyte count and lymphocyte-to-white blood cells ratio as indicators of survival in specific cancer subtypes. Int Immunopharmacol. 2019;77:105982. doi:10.1016/j.intimp.2019.105982
   PubMed Web of Science ®Google Scholar
• Mohsen A, Taalab M, Abousamra N, Mabed M. Prognostic significance of absolute lymphocyte count, absolute monocyte count, and absolute lymphocyte count to absolute monocyte count ratio in follicular non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(9):e606–e615. doi:10.1016/j.clml.2020.03.007
   PubMed Web of Science ®Google Scholar
• Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011;22(1):149–155. doi:10.1093/annonc/mdq314
   PubMed Web of Science ®Google Scholar
• Di Vito C, Navone SE, Marfia G, et al. Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. Platelets. 2017;28(6):585–594. doi:10.1080/09537104.2016.1247208
   PubMed Web of Science ®Google Scholar
• Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. doi:10.1186/s13045-018-0669-2
   PubMed Web of Science ®Google Scholar
• Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. Int J Biol Macromol. 2021;184:857–862. doi:10.1016/j.ijbiomac.2021.06.140
   PubMed Web of Science ®Google Scholar
• Matsubara T, Takamori S, Haratake N, et al. Identification of the best prognostic marker among immunonutritional parameters using serum C-Reactive protein and albumin in non-small cell lung cancer. Ann Surg Oncol. 2021;28(6):3046–3054. doi:10.1245/s10434-020-09230-x
   PubMed Web of Science ®Google Scholar
• Fan X, Zang L, Zhao BB, et al. Development and validation of prognostic scoring in primary intestinal diffuse large B-cell lymphoma: a single-institution study of 184 patients. Ann Transl Med. 2021;9(20):1542. doi:10.21037/atm-21-4761
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang H, Miao Y, et al. Multiple primary malignancies in 788 Chinese patients with diffuse large B-cell lymphoma. Cancer Med. 2023. doi:10.1002/cam4.6070
   Google Scholar
• Ulu BU, Yiğenoğlu TN, Başcı S, et al. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma. Leuk Res. 2021;110:106700. doi:10.1016/j.leukres.2021.106700
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang W, Zhou D. Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. Hematology. 2022;27(1):757–764. doi:10.1080/16078454.2022.2091197
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kang HJ, Kim JS, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011;117(6):1958–1965. doi:10.1182/blood-2010-06-288480
   PubMed Web of Science ®Google Scholar
• Lin JL, Lin JX, Li P, et al. The impact of surgery on long-term survival of patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study. Gastroenterol Res Pract. 2019;2019:9683298. doi:10.1155/2019/9683298
   PubMed Web of Science ®Google Scholar
• Wang M, Ma S, Shi W, Zhang Y, Luo S, Hu Y. Surgery shows survival benefit in patients with primary intestinal diffuse large B-cell lymphoma: a population-based study. Cancer Med. 2021;10(10):3474–3485. doi:10.1002/cam4.3882
   PubMed Web of Science ®Google Scholar
• Varelas AN, Eggerstedt M, Ganti A, Tajudeen BA. Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B -cell lymphoma. Laryngoscope. 2019;129(6):1259–1264. doi:10.1002/lary.27639
   PubMed Web of Science ®Google Scholar
• Binn M, Ruskoné-Fourmestraux A, Lepage E, et al. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol. 2003;14(12):1751–1757. doi:10.1093/annonc/mdg495
   PubMed Web of Science ®Google Scholar
• Li M, Yao H, Zhang P, et al. Development and validation of a [(18)F]FDG PET/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients. Eur Radiol. 2022;33:3354–3365. doi:10.1007/s00330-022-09301-5
   PubMed Web of Science ®Google Scholar
• He J, Chen Z, Xue Q, et al. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature. J Transl Med. 2022;20(1):186. doi:10.1186/s12967-022-03393-9
   PubMed Web of Science ®Google Scholar